荣丰控股集团股份有限公司 2023 年第一季度报告 证券代码：000668 证券简称：荣丰控股 公告编号：2023-039 荣丰控股集团股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经审计 □是 否 1 荣丰控股集团股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 适用 □不适用 | | | 单位：元 | | --- | --- | --- | | 项目 | 本报告期金额 | 说明 | | 计入当期损益的政府补助（与公司正常经营业务密切相关， | | | | 符合国家政策规定、按照一定标准定额或定量持续享受的政 | 33,653.22 ...

2022 年度青岛辖区上市公司投资者网上集体接待日活动记录表 荣丰控股集团股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |-------------------------|--------------------------------|------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | | 别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他（ 2022 | 年度青岛辖区上市公司投资者网上集体接待日） | | | 副董事长、总裁 | 王焕新女士 | | 活动参与人员 | 董事会秘书 谢高先生 | | | | 财务总监 | 吴庆女士 | | 时间 | 2022 年 11 月 3 日 | 15:00-17:00 | | 地点 | 全景路演（ | http://rs.p5w.net/ ） | | 形式 | 网络在线文字交流形式 | | | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥189,523,795.37, representing a significant increase of 1,171.96% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,556,986.43, a decrease of 31.19% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,584,009.98, reflecting a 33.59% increase compared to the previous year[4]. - The net profit for Q3 2022 was -11,848,479.78 CNY, compared to -48,240,537.98 CNY in the same period last year, indicating an improvement[25]. - The total operating profit for the quarter was 8,684,825.98 CNY, a significant recovery from a loss of -57,353,021.09 CNY in the previous year[25]. - The total comprehensive income attributable to the parent company was -27,785,192.83 CNY, an improvement from -45,334,596.42 CNY year-over-year[26]. Earnings Per Share - The basic earnings per share were -¥0.09, a decrease of 30.77% year-on-year[4]. - The diluted earnings per share were also -¥0.09, reflecting a 30.77% decline compared to the same period last year[4]. - Basic and diluted earnings per share were both -0.19 CNY, compared to -0.31 CNY in the same quarter last year[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,498,026,811.90, down 9.06% from the end of the previous year[5]. - As of September 30, 2022, total assets amounted to CNY 3,498,026,811.90, down from CNY 3,846,493,191.89 at the beginning of the year, reflecting a decrease of approximately 9.1%[22]. - The company's total liabilities decreased to CNY 1,584,940,357.43 from CNY 1,986,813,585.32, a reduction of about 20.2%[21]. - The equity attributable to shareholders increased to ¥1,229,161,545.89, marking a growth of 4.19% compared to the end of the previous year[5]. Cash Flow - The cash flow from operating activities was -¥90,988,568.63, indicating a significant decrease of 118.48% year-to-date[4]. - Cash flow from operating activities showed a net outflow of -90,988,568.63 CNY, down from a net inflow of 492,408,969.47 CNY in the same quarter last year[29]. - The company reported cash inflow from investment activities of 164,166,677.28 CNY, while cash outflow was 219,605,268.39 CNY, resulting in a net cash outflow of -55,438,591.11 CNY[29]. - Financing activities generated a cash inflow of 526,310,000.00 CNY, but the net cash outflow was -114,953,360.29 CNY, compared to -263,680,026.32 CNY in the previous year[30]. - Cash and cash equivalents were reported at CNY 82,349,479.44, a decrease from CNY 480,759,764.94 at the beginning of the year, representing a decline of approximately 82.8%[18]. - The cash and cash equivalents at the end of the period were 48,489,393.73 CNY, down from 94,037,723.76 CNY at the end of the previous year[30]. Government Subsidies and Acquisitions - The company reported government subsidies amounting to ¥3,561,887.13 for the current period, contributing to its financial performance[7]. - The company completed the acquisition of 100% equity in Hunan Weiyu Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary[17]. Share Transfer and Due Diligence - The company is in the process of transferring control to Hubei New Momentum Fund Management Co., Ltd., which will acquire approximately 29.90% of the company's shares[14]. - The company has engaged intermediaries to conduct due diligence and valuation for the ongoing share transfer process[14]. Non-Current Assets and Impairment Loss - The company’s non-current assets totaled CNY 732,052,364.22, an increase from CNY 647,387,474.81 at the beginning of the year, indicating a growth of about 13.1%[20]. - The company reported a credit impairment loss of -6,938,225.10 CNY for the quarter[25].

Financial Performance - The company's operating revenue for the reporting period reached CNY 312,499,586.98, a significant increase of 756.32% compared to CNY 36,493,418.44 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was a loss of CNY 14,228,206.40, an improvement of 44.49% from a loss of CNY 25,631,315.20 in the previous year[18]. - The basic earnings per share improved to CNY -0.1 from CNY -0.17, reflecting a 41.18% increase[18]. - The diluted earnings per share also improved to CNY -0.1 from CNY -0.17, indicating a 41.18% increase[18]. - The net profit for the first half of 2022 was ¥4,665,724.40, a significant improvement compared to a net loss of ¥27,154,037.45 in the same period of 2021[118]. - The company reported a total profit of ¥17,761,641.93 for the first half of 2022, compared to a total loss of ¥32,757,769.95 in the previous year[117]. - The total comprehensive income for the first half of 2022 was ¥4,665,724.40, contrasting with a comprehensive loss of ¥27,154,037.45 in the previous year[118]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -77,170,579.72, a decline of 120.84% compared to CNY 370,296,045.81 in the same period last year[18]. - The cash and cash equivalents decreased from CNY 480,759,764.94 at the beginning of the year to CNY 197,229,211.57 by June 30, 2022, a decline of approximately 58.9%[108]. - The net cash flow from operating activities for the first half of 2022 was -77,170,579.72 yuan, a significant decrease compared to 370,296,045.81 yuan in the same period of 2021[122]. - The total cash inflow from investment activities was 153,166,677.28 yuan, while cash outflow was 207,820,094.46 yuan, resulting in a net cash flow of -54,653,417.18 yuan[123]. - Cash inflow from financing activities totaled 499,310,000.00 yuan, with cash outflow of 514,019,567.27 yuan, leading to a net cash flow of -14,709,567.27 yuan[123]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,603,823,895.86, down 6.31% from CNY 3,846,493,191.89 at the end of the previous year[18]. - The total liabilities decreased from CNY 1,986,813,585.32 to CNY 1,674,223,237.22, a reduction of about 15.7%[110]. - The company's total equity rose from CNY 1,859,679,606.57 to CNY 1,929,600,658.64, indicating an increase of approximately 3.7%[110]. - The total amount of guarantees approved during the reporting period is CNY 35,000,000, with an actual occurrence of CNY 36,000,000[87]. - The total amount of guarantees at the end of the reporting period is CNY 46,000,000, with an actual guarantee balance of CNY 46,000,000[87]. Business Segments - The medical device business through its subsidiary, Weiyu Medical, generated revenue of approximately CNY 276.3 million, with a net profit of CNY 30.8 million during the reporting period[29]. - The orthopedic medical device market is expected to expand due to an increasing elderly population and improvements in medical insurance coverage[27]. - The real estate development segment generated revenue of ¥17,844,859.67, accounting for 5.71% of total revenue, with a year-on-year increase of 43.64%[38]. - The company’s real estate development area under construction decreased by 34.4% in the first half of 2022[26]. - The company aims to transition from real estate to the healthcare sector, focusing on the specialization and scale of its medical device business, particularly in orthopedic consumables[31]. Strategic Plans and Market Outlook - The company plans to not distribute cash dividends or issue bonus shares for the reporting period[4]. - The company plans to strengthen the integration and management of its medical segment, focusing on direct sales and expanding its product offerings in response to market opportunities[32]. - The company aims to enhance its operational strategies and adapt to policy changes to improve decision-making and resource allocation[33]. - The company plans to conduct related transactions with Ma'anshan Rural Commercial Bank, with a limit not exceeding 600 million yuan for deposits, loans, and settlement services[77]. - The company plans to actively raise funds through various channels, including deposits, loans, and asset liquidation, to ensure the fulfillment of compensation obligations[60]. Risks and Challenges - The company has outlined potential risks and uncertainties in its future plans, advising investors to be cautious[4]. - The company experienced a significant decline in the real estate market, with a 28.9% decrease in housing sales revenue, totaling ¥66,072 billion in the first half of 2022[26]. - The implementation of centralized procurement policies for high-value orthopedic consumables may lead to a significant decrease in product sales prices, posing risks to the performance of Weiyu Medical[1]. - The company is closely monitoring policy changes that could impact its operations and will adjust strategies accordingly[1]. - The company emphasizes the importance of adhering to pandemic prevention measures to mitigate potential impacts on operations[1]. Shareholder and Governance Matters - The company has established a management mechanism that balances the rights and responsibilities of shareholders, particularly protecting the interests of minority shareholders[57]. - The company has committed to maintaining a good credit status and fulfilling obligations under related agreements[61]. - The company will ensure timely disclosure of information regarding related party transactions[61]. - The company has made a commitment to ensure that all transactions do not harm the interests of the listed company or its shareholders[62]. - The company reported a commitment to maintain the independence of its operations, ensuring that management and financial activities are separate from any related parties[62]. Accounting and Financial Reporting - The financial report for the half-year period has not been audited[106]. - The company’s financial statements are reported in yuan[107]. - The company follows specific accounting policies for business combinations, measuring assets and liabilities at their book value on the merger date[147]. - The company recognizes deferred tax assets related to deductible temporary differences if new evidence indicates realizable economic benefits[148]. - The company assesses whether multiple transactions constitute a single transaction for accounting purposes[148].

Financial Performance - The company's operating revenue for 2021 was CNY 252,258,986.94, representing a 130.20% increase compared to CNY 109,583,338.38 in 2020[23] - The net profit attributable to shareholders for 2021 was CNY 235,598,142.11, a significant increase of 1,116.42% from a loss of CNY 23,179,103.91 in 2020[23] - The net cash flow from operating activities improved to CNY 114,140,038.27, a 220.52% increase from a negative cash flow of CNY 94,702,431.73 in 2020[23] - Basic earnings per share for 2021 were CNY 1.60, compared to a loss of CNY 0.16 per share in 2020, marking a 1,100.00% increase[23] - In Q4 2021, the company reported a significant revenue of CNY 200,865,381.06, with a total annual revenue of CNY 252,258,987.94[28] - The net profit attributable to shareholders in Q4 2021 was CNY 280,932,738.53, marking a recovery from previous quarterly losses[28] - The company reported non-recurring gains of CNY 378,974,253.86 for 2021, significantly higher than CNY 8,696,522.15 in 2020[30] Asset and Equity Changes - Total assets at the end of 2021 were CNY 3,846,493,191.89, a 46.85% increase from CNY 2,619,251,905.01 at the end of 2020[24] - The net assets attributable to shareholders increased by 24.95% to CNY 1,179,691,411.05 at the end of 2021, up from CNY 944,093,268.94 in 2020[24] - The company incorporated Weiyu Medical into its consolidated financial statements, contributing to substantial growth in revenue and total assets[39] - The company acquired 33.74% equity in Anhui Weiyu Medical Technology Co., Ltd., controlling a total of 76.65% of the company[51] Business Transition and Strategy - The company transitioned its main business focus from real estate development to medical device distribution and technical services following the acquisition of Weiyu Medical[34] - The company completed a major asset restructuring on October 14, 2021, expanding its business to include medical device distribution and technical services[21] - The medical device sales segment generated ¥182,739,229.35, accounting for 72.44% of total operating revenue[45] - The company plans to continue expanding its service layout in terminal medical institutions, leveraging its professional talent and extensive brand resources[42] Market and Industry Outlook - The medical device market is projected to grow due to an aging population, with 60 years and older individuals accounting for 18.7% of the population[35] - The implementation of centralized procurement policies for high-value medical consumables is expected to impact pricing and industry dynamics[36] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[133] Risks and Challenges - The company has acknowledged potential risks in its future plans and has advised investors to be cautious[5] - The company anticipates ongoing policy risks in the real estate sector, maintaining a focus on asset disposal in line with national regulations[76] - The company faces market risks in the Changchun real estate market, where inventory pressure remains high and sales have stagnated due to the pandemic[76] Governance and Management - The company emphasizes its independent governance structure, ensuring no interference from controlling shareholders in operational decisions[82] - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with regulatory requirements[83] - The company maintains a fully independent financial and operational structure, with no shared personnel or resources with controlling shareholders[85] - The company has established independent procurement and sales systems, ensuring operational autonomy[85] Shareholder Engagement - The company conducted multiple investor communications throughout 2021, focusing on shareholder inquiries and project updates[78] - The company reported a significant increase in shareholder engagement, with inquiries about shareholder numbers and project progress being common[79] - The company plans to implement a three-year shareholder return plan from 2021 to 2023[87] Employee and Training Initiatives - The total number of employees at the end of the reporting period was 387, with 384 from major subsidiaries[107] - The company plans to conduct at least 12 general training sessions and 6 professional training sessions, aiming for a training participation rate of over 95%[110] - The company emphasizes a competitive salary structure to attract and retain talent while controlling labor costs[109] Compliance and Legal Matters - The company has not faced any administrative or criminal penalties in the last five years, nor has it been involved in significant litigation or arbitration[130] - The company has confirmed that it has no history of administrative penalties, criminal penalties, or major litigation related to economic disputes in the past five years[132] - The company has committed to timely disclosures in accordance with relevant laws and regulations during the transaction process[132] Future Projections - The company provided a positive outlook for 2022, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[133] - The company has set a performance guidance of 1.8 billion RMB in revenue for the next fiscal year, indicating a strong growth trajectory[139] - The company aims to reduce operational costs by 15% through efficiency improvements and process optimization in the upcoming year[139]

Revenue and Profitability - Revenue for Q1 2022 reached ¥142,238,620.35, a significant increase of 545.24% compared to ¥22,044,465.07 in the same period last year[3] - Net profit attributable to shareholders was a loss of ¥6,226,857.91, an improvement of 30.35% from a loss of ¥8,940,057.71 in the previous year[3] - The net profit for the quarter was CNY 989,594.42, a recovery from a net loss of CNY 9,206,838.22 in the same period last year[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥12,313,089.68, worsening by 36.66% from a loss of ¥9,010,240.43 in the previous year[3] - The total comprehensive income for the period was -6,226,857.91 CNY, a decrease of 30.4% compared to the previous period's -8,940,057.71 CNY[18] Cash Flow - The net cash flow from operating activities was negative at ¥47,564,818.50, a decline of 796.32% compared to a positive cash flow of ¥6,830,913.23 in the same period last year[3] - The total cash outflow from operating activities was 277,996,203.10 CNY, compared to 36,786,587.47 CNY in the previous period, indicating increased operational expenses[20] - The total cash inflow from financing activities was 489,850,000.00 CNY, an increase of 119.5% compared to 223,350,000.00 CNY in the previous period[21] - The net cash flow from financing activities was 46,171,908.69 CNY, reversing from a negative cash flow of -24,228,698.24 CNY in the previous period[21] - The company received cash from sales of goods and services amounting to 216,085,849.32 CNY, a substantial increase from 42,078,798.02 CNY in the previous period[19] - The company received 10,000,000.00 CNY from investment recoveries during the period, with no such cash inflow reported in the previous period[20] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥3,612,818,576.58, down 6.08% from ¥3,846,493,191.89 at the end of the previous year[4] - The company's total assets decreased to CNY 3,612,818,576.58 from CNY 3,846,493,191.89 at the beginning of the year, reflecting a decline of approximately 6.1%[14] - Current assets totaled CNY 2,970,487,769.97, down from CNY 3,199,105,717.08, a decrease of about 7.1%[12] - Current liabilities decreased to CNY 1,741,552,263.52 from CNY 1,966,254,939.27, a reduction of approximately 11.5%[13] - The total liabilities decreased to CNY 1,764,149,375.60 from CNY 1,986,813,585.32, a decline of about 11.2%[14] Shareholder Information - The major shareholder, Shengshida Investment Co., Ltd., holds 40.81% of the shares, with 57,680,703 shares pledged[8] - A share transfer framework agreement was signed for the transfer of 43,905,725 shares, representing 29.90% of the company's issued shares, which may result in a change of control[10] Earnings Per Share - The basic and diluted earnings per share for Q1 2022 were both -¥0.040, an improvement of 33.33% from -¥0.060 in the same period last year[3] - The company reported a basic and diluted earnings per share of -0.040 CNY, compared to -0.060 CNY in the previous period[18] Expenses - The company reported a significant increase in management expenses to CNY 20,556,456.71 from CNY 9,206,217.78, an increase of approximately 123.5%[17] - Total operating costs amounted to CNY 142,131,299.87, compared to CNY 32,178,580.74 in the prior period, indicating an increase of about 341.5%[16]

Corporate Governance and Structure - The company has a strong governance structure and internal control procedures that support orderly business operations[38]. - The company maintains independence from its controlling shareholders in terms of personnel, finance, and operations, ensuring a complete and autonomous business structure[81]. - The company has established specialized committees within the board to oversee strategic, audit, and remuneration matters, enhancing operational oversight[80]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance approach[80]. - The company has committed to timely and accurate information disclosure, ensuring all shareholders have equal access to information[80]. - The company has established an investor relations management system to enhance communication with investors, approved on April 26, 2021[114]. - The company has implemented an associated transaction management system to ensure fairness in transactions with related parties, approved on October 26, 2021[114]. - The company has committed to maintaining a good corporate image by respecting the legitimate rights and interests of creditors, suppliers, and consumers[120]. - The company has established a management mechanism that balances the rights and responsibilities of the shareholders' meeting, board of directors, and supervisory board to protect the interests of minority shareholders[120]. - The company has committed to ensuring compliance with all relevant laws and regulations in its operations[133]. Financial Performance - The company achieved a total operating revenue of 252,258,986.94 yuan in 2021, representing a year-on-year increase of 130.20%[36]. - The net profit attributable to shareholders in 2021 was ¥235,598,142.11, a significant increase of 1,116.42% from a loss of ¥23,179,103.91 in 2020[23]. - The company's operating revenue for 2021 was ¥252,258,986.94, representing a 130.20% increase compared to ¥109,583,338.38 in 2020[23]. - The total assets at the end of 2021 were ¥3,846,493,191.89, a 46.85% increase from ¥2,619,251,905.01 at the end of 2020[24]. - The net assets attributable to shareholders increased by 24.95% to ¥1,179,691,411.05 in 2021 from ¥944,093,268.94 in 2020[24]. - The company reported a significant non-operating income of ¥378,974,253.86 in 2021, compared to ¥8,696,522.15 in 2020[31]. - The company reported a significant increase in financial expenses by 257.49% to ¥42,134,526.10 due to the consolidation of Weiyu Medical[53]. - The company reported a net cash flow from operating activities of ¥114,140,038.27, a 220.52% increase compared to the previous year[55]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year increase of 15%[89]. Business Operations and Strategy - The company completed a major asset restructuring on October 14, 2021, expanding its main business to include medical device distribution and technology services[21]. - The company has shifted its main business focus from real estate development to medical device distribution and technical services following a major asset restructuring to acquire Weiyu Medical[34]. - The company plans to enhance the marketing efforts for the Changchun International Financial Center to accelerate inventory turnover and initiate the disposal of remaining real estate assets[73]. - The company is transitioning from real estate to the medical health industry, planning to divest real estate assets while expanding its medical supply business[73]. - The company has divested from existing real estate operations, retaining only the Changchun project, which primarily offers improved residential and high-end office properties[35]. - The company plans to apply for a borrowing limit of up to CNY 5 billion from its controlling shareholder, with an annual interest rate not exceeding 9.5%[159]. - The company has established a transaction limit of up to CNY 600 million with Ma'anshan Rural Commercial Bank for deposits, loans, and related services[159]. Market and Industry Insights - The company’s medical device distribution market is expected to grow significantly due to an aging population, with 264 million people aged 60 and above projected by 2021[34]. - The average per capita medical expenditure in China rose from CNY 912 in 2013 to CNY 3,189 in 2020, indicating a growing market for medical services[34]. - The implementation of centralized procurement policies for high-value medical consumables is expected to significantly impact the medical device industry, leading to lower terminal prices[35]. - In 2021, the national real estate development investment reached CNY 14.8 trillion, with a year-on-year growth of 4.4%, but the growth rate decreased by 2.6 percentage points compared to the previous year[34]. - The area of new housing starts nationwide was 1.99 billion square meters, a year-on-year decline of 11.4%, with the decline expanding by 10.2 percentage points compared to the previous year[34]. Shareholder Engagement and Communication - The company engaged in multiple investor communications throughout 2021, focusing on shareholder inquiries and operational updates[75]. - The company reported significant interest from investors regarding the progress of the Chongqing project and the timing of quarterly earnings disclosures[76]. - The company has received inquiries about its dividend policies and shareholder numbers, indicating ongoing investor engagement[75]. - The company plans to implement a three-year shareholder return plan from 2021 to 2023, as discussed in the fourth temporary shareholders' meeting in November 2021[84]. Legal and Compliance Matters - The company has not faced any administrative or criminal penalties against the company or its executives in the last five years, ensuring a clean compliance record[129]. - The company has maintained strict confidentiality regarding any insider information related to transactions or major asset restructuring[125]. - The company has not engaged in any insider trading related to the transaction, reinforcing its commitment to ethical practices[129]. - The company has confirmed that there are no overdue debts or insolvency issues, ensuring the ability to fulfill compensation obligations[122]. - The company has committed to ensuring that the transaction will not occupy the listed company's funds or increase its risks[134]. Employee and Training Initiatives - The total number of employees at the end of the reporting period is 387, with 3 from the parent company and 384 from major subsidiaries[102]. - The company plans to conduct at least 12 general training sessions and 6 professional training sessions annually, aiming for a training participation rate of 95%[106]. - The employee composition includes 39 production personnel, 77 sales personnel, 76 technical personnel, 47 financial personnel, 55 administrative personnel, and 93 others[102]. Future Outlook and Projections - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues to reach approximately 1.32 billion RMB[89]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential mergers[89]. - The company plans to expand its market presence through strategic acquisitions, including the equity acquisition agreement for the Cimu Mountain project in Chongqing[95]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of 100 million set aside for strategic investments[128].

Financial Performance - The company's operating revenue for Q3 2021 was ¥14,900,187.44, a decrease of 29.07% compared to the same period last year[4] - The net profit attributable to shareholders was -¥19,703,281.22, representing a decline of 326.14% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥18,950,028.60, down 98.86% from the previous year[4] - The basic earnings per share for Q3 2021 was -¥0.13, a decrease of 347.27% year-on-year[4] - The weighted average return on net assets was -2.17%, down 1.58% from the previous year[4] - The net profit for the third quarter of 2021 was -48,240,537.98 CNY, compared to -21,629,548.14 CNY in the same period last year, indicating a significant increase in losses[23] - The net profit attributable to the parent company was -45,334,596.42 CNY, up from -20,800,994.38 CNY year-over-year[23] - Basic and diluted earnings per share were both -0.31 CNY, compared to -0.14 CNY in the same quarter last year[23] - The company reported a total comprehensive loss of -48,240,537.98 CNY for the quarter, compared to -25,199,002.10 CNY in the previous year[23] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥492,408,969.47, an increase of 581.40%[4] - Cash and cash equivalents increased significantly to 235,332,422.31 yuan from 66,554,513.96 yuan, indicating a growth of approximately 253%[18] - Operating cash flow for the period was 492,408,969.47 CNY, a substantial improvement from -102,287,098.00 CNY in the previous year[26] - Total cash inflow from financing activities was 1,231,400,122.51 CNY, compared to 869,000,000.00 CNY in the prior year[27] - The cash and cash equivalents at the end of the period amounted to 94,037,723.76 CNY, up from 8,803,896.96 CNY at the end of the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,007,250,716.24, reflecting a growth of 14.81% compared to the end of the previous year[4] - Total assets as of September 30, 2021, amounted to 3,007,250,716.24 yuan, an increase from 2,619,251,905.01 yuan at the end of 2020[19] - Total liabilities as of September 30, 2021, were 2,034,596,099.08 yuan, compared to 1,577,356,749.87 yuan at the end of 2020[20] - The total equity attributable to shareholders was ¥898,758,672.52, a decrease of 4.80% compared to the previous year[6] - The company’s equity attributable to shareholders decreased to 898,758,672.52 yuan from 944,093,268.94 yuan, a decline of approximately 4.8%[20] Investments and Collaborations - The company signed a cooperation agreement with the Qingdao West Coast New Area to develop a health industry cluster, focusing on medical devices and health services[12] - The company extended the management service period for a construction project with Ma'anshan Rural Commercial Bank by six months, with a service fee of ¥3,300,000[13] - The company acquired 30.15% equity in Weiyu Medical for a cash payment of 60 million yuan and completed the capital increase of 60 million yuan[15] - As of October 14, 2021, the company holds 33.74% equity in Weiyu Medical and controls 76.65% of the voting rights[15] - The company has made a total investment of 60 million yuan in Weiyu Medical as per the capital increase agreement[16] Operational Performance - Operating revenue for the current period was 51,393,605.88 yuan, up from 44,002,489.38 yuan in the previous period, representing a growth of approximately 16.3%[22] - Total operating costs increased to 114,074,545.02 yuan from 76,585,751.18 yuan, reflecting a rise of approximately 49%[22] - The company reported a net loss of 58,157,608.50 yuan for the current period, compared to a loss of 22,267,502.54 yuan in the previous period[22] Other Information - The cash outflow from investing activities was -160,760,069.53 CNY, compared to 190,949,218.68 CNY in the same period last year[27] - The company did not report any significant new product developments or market expansions during this quarter[28] - The third quarter report was not audited, indicating that the figures may be subject to change upon final review[28]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 36,493,418.44, representing a 58.70% increase compared to CNY 22,995,472.53 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was a loss of CNY 25,631,315.20, which is a 58.44% increase in loss compared to a loss of CNY 16,177,354.19 in the previous year[22]. - The net cash flow from operating activities was CNY 370,296,045.81, a significant improvement of 541.49% compared to a negative cash flow of CNY -83,874,309.90 in the same period last year[22]. - The basic earnings per share were -CNY 0.17, which is a 54.55% increase in loss compared to -CNY 0.11 in the same period last year[22]. - The company reported a total comprehensive loss of CNY 27,154,037.45 for the first half of 2021, compared to a total comprehensive loss of CNY 34,522,106.28 in the same period of 2020[133]. - The company reported a net loss of CNY 4,290,030.43 for the first half of 2021, compared to a net profit of CNY 250,579,598.41 in the same period of 2020, indicating a significant decline in profitability[135]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,827,379,261.68, reflecting a 7.95% increase from CNY 2,619,251,905.01 at the end of the previous year[22]. - The total asset value as of June 30, 2021, was CNY 2,827,379,261.68, reflecting a year-on-year increase of 7.95%[32]. - Total current liabilities rose to CNY 1,812,638,143.99, compared to CNY 1,577,356,749.87 at the end of 2020, indicating an increase of about 15%[125][126]. - The company's inventory decreased to CNY 1,431,972,035.59 from CNY 1,765,935,287.32, reflecting a decline of approximately 19%[123][126]. - The total equity attributable to shareholders decreased to CNY 918,461,953.74 from CNY 944,093,268.94, a reduction of about 2.7%[126]. Business Operations - The company's main business is real estate development, focusing on self-developed sales, with the primary product being improved residential and high-end office properties[30]. - The real estate market in Changchun saw a new supply of 405.7 million square meters and a transaction area of 399.3 million square meters, with a year-on-year increase of 4.1%[30]. - The average transaction price for residential properties in Changchun increased by 2.7% year-on-year, reaching CNY 8,730 per square meter[30]. - The real estate development segment contributed ¥15,924,926.68, accounting for 43.64% of total revenue, with a year-on-year growth of 105.45%[42]. - The property management and leasing segment generated ¥20,568,491.76, representing 56.36% of total revenue, with a year-on-year increase of 34.93%[42]. Financial Strategy and Future Plans - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[6]. - The company plans to transform its main business by divesting from real estate and injecting assets related to the healthcare industry, aiming to enhance profitability and sustainable development capabilities[31]. - The company plans to continue monitoring national policies closely, particularly the "housing is for living, not for speculation" principle, which is expected to remain in place[55]. - The company intends to apply for a borrowing limit of up to 500 million yuan from its controlling shareholder, with an interest rate not exceeding 9.5% and a term of one year[84]. - Future outlook includes potential strategies for mergers and acquisitions to drive growth[146]. Governance and Compliance - The company has a stable management team with a strong professional background and a unique corporate culture, ensuring effective governance and operational efficiency[37]. - The company has established a robust internal control system to safeguard the interests of minority shareholders[66]. - The company has not engaged in any violations regarding external guarantees during the reporting period[72]. - The company has not experienced any significant changes in its profit structure or sources during the reporting period[40]. - There were no changes in the board of directors or senior management during the reporting period[60]. Risks and Challenges - The company has acknowledged potential risks in its future plans and has advised investors to be cautious regarding investment risks[5]. - The real estate market in Changchun is experiencing significant inventory pressure, leading to a supply-demand imbalance[56]. - The acquisition of Weiyu Medical is anticipated to enhance the company's market position, although it faces integration risks due to differences in business systems and cultures[55]. Shareholder Information - The company has 6,824 ordinary shareholders at the end of the reporting period[106]. - The largest shareholder, Shengshida Investment Co., Ltd., holds 40.81% of the shares, amounting to 59,926,083 shares, with 57,680,703 shares pledged[106]. - The second-largest shareholder, Linglong Group Co., Ltd., holds 4.97% of the shares, amounting to 7,300,000 shares[106]. Legal Matters - There are no major litigation or arbitration matters during the reporting period[75]. - The company reached a settlement with Shenyang Yuanda Aluminum Engineering Co., Ltd. regarding a construction contract dispute, with a total amount involved of approximately RMB 8.04 million[75]. - The company has filed a lawsuit against Ziheng Sunshine for unpaid equipment fees and management fees totaling RMB 3.91 million, with a court ruling in favor of the company[76]. Financial Reporting - The semi-annual financial report has not been audited[73]. - The financial report for the first half of 2021 has not been audited[121]. - The company’s financial statements are prepared based on the going concern assumption, indicating normal operational and financial conditions[164]. - The company adheres to the accounting policies and estimates in accordance with the relevant enterprise accounting standards, ensuring accurate financial reporting[165].

Financial Performance - The company's operating revenue for 2020 was ¥109,583,338.38, a decrease of 73.84% compared to ¥418,864,406.50 in 2019[19] - The net profit attributable to shareholders for 2020 was a loss of ¥23,179,103.91, representing a decline of 163.25% from a profit of ¥36,647,705.01 in 2019[19] - The basic earnings per share for 2020 was -¥0.16, down 164.00% from ¥0.25 in 2019[19] - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of ¥31,875,626.06 in 2020 compared to a profit of ¥38,512,342.74 in 2019, a drop of 182.77%[19] - The weighted average return on net assets for 2020 was -2.41%, down from 4.52% in 2019, indicating a significant decline in profitability[19] - The company reported a net profit of -12,669,674 yuan from Beijing Rongfeng Real Estate Development Co., Ltd. and a net profit of 11,714,250.4 yuan from Changchun Rongfeng Real Estate Development Co., Ltd.[65] - The company reported a net loss of approximately ¥23.18 million for the year 2020, resulting in no cash dividends being distributed[75] Cash Flow and Assets - The net cash flow from operating activities improved by 49.19%, reaching -¥94,702,431.73 in 2020 compared to -¥186,379,001.02 in 2019[19] - Total assets at the end of 2020 were ¥2,619,251,905.01, a decrease of 3.47% from ¥2,713,537,312.07 at the end of 2019[19] - The total amount of accounts receivable at the end of 2020 was ¥22,440,163.50, representing 0.86% of total assets, up from 0.10% at the beginning of the year[54] - The inventory value decreased by 5.84% to ¥1,765,935,287.32, accounting for 67.42% of total assets, down from 73.26%[54] - The company's cash and cash equivalents decreased significantly by 99.74%, resulting in a net decrease of ¥163,467,050.21[51] - Cash and cash equivalents decreased significantly to CNY 66,554,513.96 from CNY 288,586,281.89, a drop of approximately 77.0%[182] Revenue Breakdown - Revenue from real estate development was 77,937,478.11 yuan, accounting for 71.12% of total revenue, down 80.63% year-on-year[40] - In 2020, the company's total revenue from commodity housing sales was ¥54,204,661, accounting for 69.66% of operating costs, a decrease of 69.26% compared to ¥176,315,894.71 in 2019[46] - Revenue from property management, leasing, and other services increased by 63.49% to ¥23,611,658.47, representing 30.34% of operating costs, compared to ¥14,441,993.30 in 2019[46] Strategic Initiatives - The company plans to shift its focus from real estate to the healthcare sector to enhance profitability and growth potential[30] - The company initiated a major asset restructuring to acquire 100% equity of Wuhu Dongxu Weiyu Medical Device Technology Co., Ltd. and plans to enter the health industry[35] - The company plans to gradually divest its real estate assets and transition its main business towards the healthcare industry to cultivate new growth points[66] - The company is preparing for a major asset restructuring to enter the healthcare sector, aiming for sustainable development[67] Governance and Management - The company maintained a stable management team and governance structure, ensuring operational continuity despite market challenges[31] - The company has established a robust internal control system to protect the interests of shareholders, especially minority shareholders[110] - The board of directors consists of 7 members, including 3 independent directors, and operates through four specialized committees: Strategy, Audit, Nomination, and Compensation[154] - The management team is composed of individuals with diverse professional backgrounds, enhancing the company's governance and strategic direction[135][136][137][138][139] Shareholder and Investor Relations - The company has engaged in 31 investor communication activities during the reporting period, primarily through phone calls[72] - The company has been actively discussing the progress of the Weiyu project with investors throughout the year[72] - The company has not disclosed any significant undisclosed information during investor communications[72] Future Outlook and Risks - The company has indicated potential risks in its future plans, which may affect investment decisions[5] - The company anticipates that the real estate market will continue to face regulatory stability under the "housing is for living, not for speculation" policy[66] - The company acknowledges market risks in Changchun's real estate market, where supply exceeds demand, and plans to innovate marketing strategies to meet sales targets[68] Financial Audit and Compliance - The audit opinion for the financial statements was a standard unqualified opinion, indicating compliance with accounting standards[172] - The company has not identified any significant internal control deficiencies during the reporting period[165] - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2020[167]